Icotrokinra, an oral IL-23 receptor-targeted peptide, showed superior efficacy in achieving skin clearance (IGA 0/1 and PASI 90) compared to placebo and the oral TYK2 inhibitor deucravacitinib in two large phase 3 trials.
Both ICONIC-ADVANCE 1 and 2 demonstrated robust clinical responses at week 16 with significant treatment differences favoring icotrokinra (p<0.0001).
The safety profile of icotrokinra was favorable, with adverse event rates comparable to placebo and lower than deucravacitinib at week 24.
This advances therapeutic options for moderate-to-severe plaque psoriasis by combining convenience of oral administration with potent IL-23 pathway inhibition.
